Connection

Co-Authors

This is a "connection" page, showing publications co-authored by WEIYA XIA and HIROHITO YAMAGUCHI.
Connection Strength

0.778
  1. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer. 2018 Jan; 25(1):74-80.
    View in: PubMed
    Score: 0.150
  2. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.
    View in: PubMed
    Score: 0.054
  3. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun. 2021 05 13; 12(1):2788.
    View in: PubMed
    Score: 0.049
  4. Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2020 Jan 29; 11(1):673.
    View in: PubMed
    Score: 0.045
  5. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019 11 08; 10(1):5114.
    View in: PubMed
    Score: 0.044
  6. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 2019 05; 156(6):1849-1861.e13.
    View in: PubMed
    Score: 0.042
  7. Targeting PKCd as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell. 2018 12 10; 34(6):954-969.e4.
    View in: PubMed
    Score: 0.041
  8. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018 02 12; 33(2):187-201.e10.
    View in: PubMed
    Score: 0.039
  9. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017 Jul 15; 23(14):3711-3720.
    View in: PubMed
    Score: 0.037
  10. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016 Dec 12; 30(6):925-939.
    View in: PubMed
    Score: 0.036
  11. GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 2016 Aug 30; 7(35):57131-57144.
    View in: PubMed
    Score: 0.035
  12. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
    View in: PubMed
    Score: 0.035
  13. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res. 2016 Mar 15; 76(6):1451-62.
    View in: PubMed
    Score: 0.034
  14. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am J Transl Res. 2015; 7(6):1009-20.
    View in: PubMed
    Score: 0.033
  15. Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. Am J Transl Res. 2014; 6(6):649-63.
    View in: PubMed
    Score: 0.031
  16. Epithelial-mesenchymal transition induced by TNF-a requires NF-?B-mediated transcriptional upregulation of Twist1. Cancer Res. 2012 Mar 01; 72(5):1290-300.
    View in: PubMed
    Score: 0.026
  17. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Mol Cancer Ther. 2011 Aug; 10(8):1327-36.
    View in: PubMed
    Score: 0.025
  18. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 2009 Aug; 8(8):2375-82.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.